Ikarian Capital’s Sage Therapeutics SAGE Stock Holding History

Ikarian Capital’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-17,805	Closed	-$747K	–	154
2023 Q1	$747K	Sell	17,805 -50,000	-74%	-$2.15M	0.17%	86
2022 Q4	$2.59M	Sell	67,805 -90,000	-57%	-$3.44M	0.62%	39
2022 Q3	$6.18M	Buy	+157,805	New	+$6.1M	1.23%	29
2022 Q2	–	Sell	-249,907	Closed	-$8.38M	–	195
2022 Q1	$8.27M	Buy	+249,907	New	+$9.39M	1.09%	26
2021 Q2	–	Sell	-91,151	Closed	-$6.44M	–	270
2021 Q1	$6.82M	Buy	91,151 +25,000	+38%	+$2.05M	0.23%	98
2020 Q4	$5.72M	Sell	66,151 -50,000	-43%	-$3.69M	0.25%	86
2020 Q3	$7.1M	Sell	116,151 -85,000	-42%	-$4.31M	0.51%	48
2020 Q2	$8.36M	Buy	201,151 +18,100	+10%	+$657K	0.67%	48
2020 Q1	$5.26M	Buy	183,051 +50,051	+38%	+$2.9M	0.4%	62
2019 Q4	$9.6M	Buy	+133,000	New	+$16.4M	1.56%	16

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ikarian Capital's SAGE Position: Q2 2023 in Review

Ikarian Capital sold out of Sage Therapeutics (SAGE) in Q2 2023, closing a stake of 17,805 shares — an estimated $747K sold.

Ikarian Capital first reported a position in SAGE in Q4 2019 and held it in 10 quarters. The position peaked at $9.6M in Q4 2019. 224 funds tracked by Wall St. Rank hold SAGE as of Q2 2023.

Ikarian Capital reported no remaining Sage Therapeutics position as of Q2 2023 after selling out during the quarter.
Ikarian Capital sold 17,805 Sage Therapeutics shares in Q2 2023, an estimated $747K.
Ikarian Capital first reported a position in Sage Therapeutics in Q4 2019 and held it in 10 quarters.
Ikarian Capital's Sage Therapeutics position peaked at $9.6M in Q4 2019.
224 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2023.

Based on Ikarian Capital's 13F filing for Q2 2023, filed 14 Aug 2023.